Aβ-immunotherapy for Alzheimer's disease using mannan-amyloid-beta peptide immunoconjugates

DNA and Cell Biology

Volumn 25, Issue 10, 2006, Pages 571-580

  Ghochikyan, Anahit ^a   Petrushina, Irina ^b   Lees, Andrew ^c   Vasilevko, Vitaly ^b   Movsesyan, Nina ^a   Karapetyan, Adrine ^b   Agadjanyan, Michael G ^a,b   Cribbs, David H ^b,d  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Biosynexus Incorporated   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-28]; ANTIBODY CONJUGATE; B LYMPHOCYTE ANTIGEN; EPITOPE; MANNAN; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG; AN-1792; PEPTIDE;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; B6SJL MOUSE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CLINICAL STUDY; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DESIGN; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MENINGOENCEPHALITIS; MOUSE; MOUSE STRAIN; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; RISK FACTOR; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; IMMUNOLOGY; METHODOLOGY; PROTEIN TERTIARY STRUCTURE;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPITOPES, B-LYMPHOCYTE; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RISK FACTORS;

EID: 33846430934     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.25.571     Document Type: Article

References (65)

1. AGADJANYAN, M.G., GHOCHIKYAN, A., PETRUSHINA, I., VASILEVKO, V., MOVSESYAN, N., MKRTICHYAN, M., SAING, T., and CRIBBS, D.H. (2005). Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174, 1580-1586.
2. AHARONI, R., TEITELBAUM, D., LEITNER, O., MESHORER, A., SELA, M., and ARNON, R. (2000). Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. USA 97, 11472-11477.
3. APOSTOLOPOULOS, V., and MCKENZIE, I.F. (2001). Role of the mannose receptor in the immune response. Curr. Mol. Med. 1, 469-474.
4. APOSTOLOPOULOS, V., PIETERSZ, G.A., LOVELAND, B.E., SANDRIN, M.S., and MCKENZIE, I.F. (1995). Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. USA 92, 10128-10132.
5. APOSTOLOPOULOS, V., PIETERSZ, G.A., and MCKENZIE, I.F. (1996). Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14, 930-938.
6. APOSTOLOPOULOS, V., BARNES, N., PIETERSZ, G.A., and MCKENZIE, I.F.C. (2000). Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 18, 3174-3184.
7. AREND, W.P., and DAYER, J.-M. (1995). Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum. 38, 151-160.
8. BARD, F., CANNON, C., BARBOUR, R., BURKE, R.L., GAMES, D., GRAJEDA, H., GUIDO, T., HU, K., HUANG, J., JOHNSON-WOOD, K., et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919.
9. BAYER, A.J., BULLOCK, R., JONES, R.W., WILKINSON, D., PATERSON, K.R., JENKINS, L., MILLAIS, S.B., and DONOGHUE, S. (2005). Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64, 94-101.
10. CRIBBS, D.H., and AGADJANYAN, M.G. (2005). Immunotherapy for Alzheimer's disease: Potential problems and possible solutions. Curr. Immunol. Rev. 1, 139-155.
11. CRIBBS, D.H., LEES, A., GHOCHIKYAN, A., VASILEVKO, V., PETRUSHINA, I., BABIKYAN, D., MOVSESYAN, N., TRAN, M.A.D., and AGADJANYAN, M.G. (2003a). Mannan as a molecular adjuvant for Aβ-immunotherapy. In: Collection of Selected Free Papers of the 6th International Conference on Progress in Alzheimer's and Parkinson's Disease AP/DP-New Trends in Alzheimer and Parkinson Related Disorders I. Hanin, A. Fisher, and R. Cacabelos, eds (Monduzzi Editore, Seville, Spain), pp. 81-85.
12. CRIBBS, D.H., GHOCHIKYAN, A., TRAN, M., VASILEVKO, V., PETRUSHINA, I., SADZIKAVA, N., KESSLAK, P., KIEBER-EMMONS, T., COTMAN, C.W., and AGADJANYAN, M.G. (2003b). Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 15, 505-514.
13. DAS, P., CHAPOVAL, S., HOWARD, V., DAVID, C.S., and GOLDE, T.E. (2003). Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies. Neurobiol. Aging 24, 969-976.
14. DODART, J.C., BALES, K.R., GANNON, K.S., GREENE, S.J., DEMATTOS, R.B., MATHIS, C., DELONG, C.A., WU, S., WU, X., HOLTZMAN, D.M., et al. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5, 452-457.
15. ENGERING, A.J., CELLA, M., FLUITSMA, D.M., HOEFSMIT, E.C., LANZAVECCHIA, A., and PIETERS, J. (1997a). Mannose receptor mediated antigen uptake and presentation in human dendritic cells. Adv. Exp. Med. Biol. 417, 183-187.
16. ENGERING, A.J., CELLA, M., FLUITSMA, D., BROCKHAUS, M., HOEFSMIT, E.C., LANZAVECCHIA, A., and PIETERS, J. (1997b). The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 27, 2417-2425.
17. FERRER, I., ROVIRA, M.B., GUERRA, M.L.S., REY, M.J., and COSTA-JUSSA, F. (2004). Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14, 11-20.
18. FINKELMAN, F.D., HOLMES, J., KATONA, I.M., URBAN, J.F., BECKMANN, M.P., PARK, L.S., SCHOOLEY, K.A., COFFMAN, R.L., MOSSMANN, T.R., and PAUL, W.E. (1990). Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8, 303-333.
19. FOX, N.C., BLACK, R.S., GILMAN, S., ROSSOR, M.N., GRIFFITH, S.G., JENKINS, L., and KOLLER, M. (2005). Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563-1572.
20. GEVORKIAN, G., PETRUSHINA, I., MANOUCHARIAN, K., GHOCHIKYAN, A., ACERO, G., VASILEVKO, V., CRIBBS, D.H., and AGADJANYAN, M.G. (2004). Mimotopes of conformational epitopes in fibrillar beta-amyloid. J. Neuroimmunol. 156, 10-20.
21. GHIRAN, I., BARBASHOV, S.F., KLICKSTEIN, L.B., TAS, S.W., JENSENIUS, J.C., and NICHOLSON-WELLER, A. (2000). Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J. Exp. Med. 192, 1797-1808.
22. GHOCHIKYAN, A., VASILEVKO, V., PETRUSHINA, I., TRAN, M., SADZIKAVA, N., BABIKYAN, D., MOVSESYAN, N., TIAN, W., ROSS, T.M., CRIBBS, D.H., et al. (2003). Generation and characterization of the humoral immune response to DNA immunization with a chimeric β-amyloid-interleukin-4 minigene. Eur. J. Immunol. 33, 3232-3241.
23. GILMAN, S., KOLLER, M., BLACK, R.S., JENKINS, L., GRIFFITH, S.G., FOX, N.C., EISNER, L., KIRBY, L., ROVIRA, M.B., FORETTE, F., et al. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562.
24. GOLDE, T.E. (2005). The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 15, 84-87.
25. GRÖCER, M., HOLNTHONER, W., MAURER, D., LECHLEITNER, S., WOLFF, K., MAYR, B.B., LUBITZ, W., and PETZELBAUER, P. (2000). Dermal microvascular endothelial cells express the 180-kDa macrophage mannose receptor in situ and in vitro. J. Immunol. 165, 5428-5434.
26. HARDY, J., and SELKOE, D.J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
27. HARDY, J.A., and HIGGINS, G.A. (1992). Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
28. HOCK, C., KONIETZKO, U., STREFFER, J.R., TRACY, J., SIGNORELL, A., MULLER-TILLMANNS, B., LEMKE, U., HENKE, K., MORITZ, E., GARCIA, E., et al. (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554.
29. INMAN, J.K. (1993). Syntheses of macromolecular immunomodulators and conjugates employing haloacetyl reagents. Ann. N Y Acad. Sci. 685, 347-350.
30. JANUS, C., PEARSON, J., MCLAURIN, J., MATHEWS, P.M., JIANG, Y., SCHMIDT, S.D., CHISHTI, M.A., HORNE, P., HESLIN, D., FRENCH, J., et al. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
31. KARANIKAS, V., HWANG, L.A., PEARSON, J., ONG, C.S., APOSTOLOPOULOS, V., VAUGHAN, H., XING, P.X., JAMIESON, G., PlETERSZ, G., TAIT, B., et al. (1997). Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100, 2783-2792.
32. KOZONO, Y., ABE, R., KOZONO, H., KELLY, R.G., AZUMA, T., and HOLERS, V.M. (1998). Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J. Immunol. 160, 1565-1572.
33. KUTZLER, M.A., CAO, C., BAI, Y., DONG, H., CHOE, P.Y., SAULINO, V., MCLAUGHLIN, L., WHELAN, A., CHOO, A.Y., WEINER, D.B., et al. (2006). Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine 24, 4630-4639.
34. LEES, A., NELSON, B.L., and MOND, J.J. (1996). Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14, 190-198.
35. LINEHAN, S.A., MARTINEZ-POMARES, L., and GORDON, S. (2000). Mannose receptor and scavenger receptor: Two macrophage pattern recognition receptors with diverse functions in tissue homeostasis and host defense. Adv. Exp. Med. Biol. 479, 1-14.
36. MASLIAH, E., HANSEN, L., ADAME, A., CREWS, L., BARD, F., LEE, C., SEUBERT, P., GAMES, D., KIRBY, L., and SCHENK, D. (2005). Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131.
37. MELAURIN, J., CECAL, R., KIERSTEAD, M.E., TIAN, X., PHINNEY, A.L., MANEA, M., FRENCH, J.E., LAMBERMON, M.H., DARABIE, A.A., BROWN, M.E., et al. (2002). Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 1263-1269.
38. MOLINA, H., HOLERS, V.M., LI, B., FUNG, Y., MARIATHASAN, S., GOELLNER, J., STRAUSS-SCHOENBERGER, J., KARR, R.W., and CHAPLIN, D.D. (1996). Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA 93, 3357-3361.
39. MORGAN, D., DIAMOND, D.M., GOTTSCHALL, P.E., UGEN, K.E., DICKEY, C., HARDY, J., DUFF, K., JANTZEN, P., DICARLO, G., WILCOCK, D., et al. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
40. NICOLL, J.A., WILKINSON, D., HOLMES, C., STEART, P., MARKHAM, H., and WELLER, R.O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat. Med. 9, 448-452.
41. O'SHEA, J.J., MA, A., and LIPSKY, P. (2001). Cytokines and autoimmunity. Nat. Rev. Immun. 2, 37-45.
42. OKAWA, Y., HOWARD, C.R., and STEWARD, M.W. (1992). Production of anti-peptide specific antibody in mice following immunization with peptides conjugated to mannan. J. Immunol. Methods 149, 127-131.
43. PETRUSHINA, I., TRAN, M., SADZIKAVA, N., GHOCHIKYAN, A., VASILEVKO, V., AGADJANYAN, M.G., and CRIBBS, D.H. (2003). Importance of IgG2c isotype in the immune response to b-amyloid in APP/Tg mice. Neurosci. Lett. 338, 5-8.
44. PETRUSHINA, I., MAMIKONYAN, G., GHOCHIKYAN, A., MKRTICHYAN, M., MOVSESYAN, N., KARAPETYAN, A., LEES, A., AGADJANYAN, M.G., and CRIBBS, D.H. (2006). Active immunization of APP/Tg2576 mice with mannan-Ab28 antigen induced clearance of Ab plaques and microhemorrhages in the brains of vaccinated animals. Am. J. Pathol. (submitted).
45. PRICE, D.L., and SISODIA, S.S. (1994). Cellular and molecular biology of Alzheimer's disease and animal models. Annu. Rev. Med. 45, 435-446.
46. RETH, M., and WIENANDS, J. (1997). Initiation and processing of signals from B cell antigen receptor. Annu. Rev. Immunol. 15, 453-479.
47. SCHENK, D., BARBOUR, R., DUNN, W., GORDON, G., GRAJEDA, H., GUIDO, T., HU, K., HUANG, J., JOHNSON-WOOD, K., KHAN, K., et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
48. SEABROOK, T.J., IGLESIAS, M., BLOOM, J.K., SPOONER, E.T., and LEMERE, C.A. (2004). Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice. Vaccine 22, 4075-4083.
49. SIGURDSSON, E.M., KNUDSEN, E., ASUNI, A., FITZER-ATTAS, C., SAGE, D., QUARTERMAIN, D., GONI, F., FRANGIONE, B., and WISNIEWSKI, T. (2004). An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci. 24, 6277-6282.
50. SMELTZ, R.B., and SWANBORG, R.H. (1998). Concordance and contradiction concerning cytokines and chemokines in experimental demyelinating disease. J. Neurosci. Res. 51, 147-153.
51. SOLOMON, B., KOPPEL, R., HANAN, E., and KATZAV, T. (1996). Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. USA 93, 452-455.
52. STAMBAS, J., PIETERSZ, G., MCKENZIE, I., and CHEERS, C. (2002a). Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine 20, 1068-1078.
53. STAMBAS, J., PIETERSZ, G., MCKENZIE, I., NAGABHUSHANAM, V., and CHEERS, C. (2002b). Oxidised mannan-listeriolysin O conjugates induce Th1/Th2 cytokine responses after intranasal immunisation. Vaccine 20, 1877-1886.
54. STAMBAS, J., BROWN, S.A., GUTIERREZ, A., SEALY, R., YUE, W., JONES, B., LOCKEY, T.D., ZIRKEL, A., FREIDEN, P., BROWN, B., et al. (2005). Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 23, 2454-2464.
55. SWANBORG, R.H. (2001). Experimental autoimmune encephalomyelitis in the rat: Lessons in T-cell immunology and autoreactivity. Immunol. Rev. 184, 129-135.
56. TENNER, A.J. (1999). Membrane receptors for soluble defense collagens. Curr. Opin. Immunol. 11, 34-41.
57. TURNER, M.W. (1996). Mannose-binding lectin: The pluripotent molecule of the innate immune system. Immunol. Today 17, 532-540.
58. VASTA, G.R., QUESENBERRY, M., AHMED, H., and O'LEARY, N. (1999). C-type lectins and galectins mediate innate and adaptive immune functions: Their roles in the complement activation pathway. Dev. Comp. Immunol. 23, 401-420.
59. VAUGHAN, H.A., HO, D.W., KARANIKAS, V.A., ONG, C.S., HWANG, L.A., PEARSON, J.M., MCKENZIE, I.F., and PlETERSZ, G. A. (1999). Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates. Vaccine 17, 2740-2752.
60. VAUGHAN, H.A., HO, D.W., KARANIKAS, V., SANDRIN, M.S., MCKENZIE, I.F., and PIETERSZ, G.A. (2000). The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan. Vaccine 18, 3297-3309.
61. WAGLE, N.M., CHENG, P., KIM, J., SPROUL, T.W., KAUSCH, K.D., and PIERCE, S.K. (2000). B lymphocyte signaling receptors and the control of class II antigen processing. Curr. Topics Microbiol. 245, 106-126.
62. WEINER, H.L., and SELKOE, D.J. (2002). Inflammation and therapeutic vaccination in CNS diseases. Nature 420, 879-884.
63. WEINER, H.L., LEMERE, C.A., MARON, R., SPOONER, E.T., GRENFELL, T.J., MORI, C., ISSAZADEH, S., HANCOCK, W.W., and SELKOE, D.J. (2000). Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48, 567-579.
64. WILCOCK, D.M., ROJIANI, A., ROSENTHAL, A., SUBBARAO, S., FREEMAN, M.J., GORDON, M.N., and MORGAN, D. (2004a). Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflamm. 1, 24.
65. WILCOCK, D.M., ROJIANI, A., ROSENTHAL, A., LEVKOWITZ, G., SUBBARAO, S., ALAMED, J., WILSON, D., WILSON, N., FREEMAN, M.J., GORDON, M.N., et al. (2004b). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24, 6144-6151.